OneOme expands leadership team in preparation for mid-year launch of its comprehensive pharmacogenomic test

MINNEAPOLIS, March 17, 2016 /PRNewswire/ -- OneOme, LLC, a pharmacogenomics company, announced today the hiring of Dr. Justin Odegaard, M.D., Ph.D. and Ross Higgins to manage and lead their pharmacogenomics testing laboratory. Both Dr. Odegaard and Mr. Higgins bring extensive background in laboratory medicine and clinical practice to the OneOme team in preparation for launching the OneOme RightMed™ pharmacogenomics test of 23 genes covering more than 250 medications across a spectrum of therapeutic areas.

Dr. Odegaard currently practices at Stanford University Hospital and is both lab and medical director at Guardant Health.  He was also previously the director of molecular pathology at LifeCode, a start-up company focused on the genetic basis of human disease. As the laboratory director, Dr. Odegaard will have sign-out responsibilities for the OneOme RightMed pharmacogenomics test. "I'm passionate about improving patient care and through pharmacogenomics, we can guide optimal drug selection for patients to maximize therapeutic effects, improve outcomes, and minimize toxicity," stated Dr. Justin Odegaard.

Ross Higgins joins OneOme as the director of laboratory operations and will oversee all day to day activities within the lab. Previously, Ross served as the lab supervisor at Health Diagnostic Laboratory followed by several years with Douglas Scientific in business development and product management roles.

OneOme plans to launch its RightMed pharmacogenomics test mid year which consists of a 23-gene panel that covers more than 250 medications for cancer, depression/anxiety, hypertension, arrhythmias, migraines, psychoses, pain, diabetes and more. "The demand for a high-quality, low cost, comprehensive pharmacogenomics test is high both in the US and internationally," stated Paul Owen, president and chief operating officer. "We have identified several early partners and opportunities for pilots to broaden the utility and value of  the RightMed test from health systems, executive health programs, ACOs and others."

About OneOme
OneOme's RightMed™ pharmacogenomics test helps healthcare providers with timely, evidence-based prescription decisions by combining a patient's genetic profile and current medications in an interactive report that easily integrates into current practices. OneOme's RightMed test covers cardiovascular disease, cancer, chronic pain, diabetes, psychiatric conditions, and more. The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care.

SOURCE OneOme, LLC

Related Links

http://www.oneome.com